<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Spring Bank Pharmaceuticals, Inc.

    Spring Bank Pharmaceuticals, Inc.

    Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...

    Spring Bank is a clinical-stage biopharmaceutic...

    Filing Type:    PU
    Novelion Therapeutics Inc.

    Novelion Therapeutics Inc.

    Novelion Therapeutics Inc. (“Novelion"), headquartered in Vancouver, British Col...

    Novelion Therapeutics Inc. (“Novelion"), head...

    Filing Type:    PU
    Spero Therapeutics, Inc.

    Spero Therapeutics, Inc.

    Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical compan...

    Spero Therapeutics, Inc. is a multi-asset, clin...

    Filing Type:    PU
    Viemed Healthcare, Inc.

    Viemed Healthcare, Inc.

    Viemed Healthcare Inc is a high level service provider using best in class technol...

    Viemed Healthcare Inc is a high level service p...

    Filing Type:    PU
    Chembio Diagnostics, Inc.

    Chembio Diagnostics, Inc.

    Chembio is a leading point-of-care diagnostics company focused on detecting and di...

    Chembio is a leading point-of-care diagnostics ...

    Filing Type:    PU
    ViewRay, Inc.

    ViewRay, Inc.

    ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdianÂŽ the wor...

    ViewRayÂŽ Inc., (NASDAQ:VRAY), designs, manufac...

    Filing Type:    PU
    Harpoon Therapeutics, Inc.

    Harpoon Therapeutics, Inc.

    Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel ...

    Harpoon Therapeutics is a clinical-stage immuno...

    Filing Type:    PU
    Compugen Ltd.

    Compugen Ltd.

    Compugen is a drug discovery company with a unique, broadly applicable, predictive...

    Compugen is a drug discovery company with a uni...

    Filing Type:    PU
    Surface Oncology, Inc.

    Surface Oncology, Inc.

    Surface Oncology is an immuno-oncology company on a mission to break through and d...

    Surface Oncology is an immuno-oncology company ...

    Filing Type:    PU
    Erytech Pharma S.A.

    Erytech Pharma S.A.

    Founded in Lyon, France in 2004, ERYTECH is a clinical-stage biopharmaceutical com...

    Founded in Lyon, France in 2004, ERYTECH is a c...

    Filing Type:    PU
    Cyclacel Pharmaceuticals, Inc.

    Cyclacel Pharmaceuticals, Inc.

    Cyclacel's founding scientist, Professor Sir David Lane, a globally recognized aut...

    Cyclacel's founding scientist, Professor Sir Da...

    Filing Type:    PU
    Omeros Corporation

    Omeros Corporation

    Omeros is a commercial-stage biopharmaceutical company committed to discovering, d...

    Omeros is a commercial-stage biopharmaceutical ...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.